UV7 Stock Overview
A digital health company, delivers diagnostic and therapeutic solutions to enhance attention cognitive function in Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
TALi Digital Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.0005 |
| 52 Week High | AU$0.006 |
| 52 Week Low | AU$0.0005 |
| Beta | 1.65 |
| 11 Month Change | 0% |
| 3 Month Change | -50.00% |
| 1 Year Change | 0% |
| 33 Year Change | -93.33% |
| 5 Year Change | -98.41% |
| Change since IPO | -99.99% |
Recent News & Updates
Recent updates
Shareholder Returns
| UV7 | DE Healthcare Services | DE Market | |
|---|---|---|---|
| 7D | 0% | -0.1% | -0.02% |
| 1Y | 0% | -32.5% | 8.2% |
Return vs Industry: UV7 exceeded the German Healthcare Services industry which returned -33% over the past year.
Return vs Market: UV7 underperformed the German Market which returned 7.4% over the past year.
Price Volatility
| UV7 volatility | |
|---|---|
| UV7 Average Weekly Movement | 96.6% |
| Healthcare Services Industry Average Movement | 5.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: UV7's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: UV7's weekly volatility has decreased from 121% to 97% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | n/a | n/a | www.talidigital.com.au |
TALi Digital Limited, a digital health company, delivers diagnostic and therapeutic solutions to enhance attention cognitive function in Australia. The company provides TALi DETECT, an evidence-based digital screening tool and training module; and TALi TRAIN, a play-based interactions therapy. It also focuses to deliver a series of product developments relevant to attention deficit hyperactivity and disorder; and autism spectrum disorder.
TALi Digital Limited Fundamentals Summary
| UV7 fundamental statistics | |
|---|---|
| Market cap | €3.08m |
| Earnings (TTM) | -€1.95m |
| Revenue (TTM) | €91.25k |
33.8x
P/S Ratio-1.6x
P/E RatioIs UV7 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| UV7 income statement (TTM) | |
|---|---|
| Revenue | AU$146.23k |
| Cost of Revenue | AU$451.55k |
| Gross Profit | -AU$305.32k |
| Other Expenses | AU$2.81m |
| Earnings | -AU$3.12m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.00095 |
| Gross Margin | -208.80% |
| Net Profit Margin | -2,131.63% |
| Debt/Equity Ratio | 0% |
How did UV7 perform over the long term?
See historical performance and comparison